Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Shares of Ekso Bionics Holdings (NASDAQ:EKSO) opened at 1.25 on Wednesday. The firm’s 50 day moving average price is $1.49 and its 200-day moving average price is $2.20. Ekso Bionics Holdings has a 1-year low of $0.99 and a 1-year high of $6.38. The company’s market capitalization is $32.24 million.
ILLEGAL ACTIVITY WARNING: This news story was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/09/15/ekso-bionics-holdings-inc-ekso-rating-lowered-to-hold-at-zacks-investment-research.html.
In other Ekso Bionics Holdings news, insider Russ Angold sold 28,254 shares of Ekso Bionics Holdings stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $1.53, for a total transaction of $43,228.62. Following the completion of the sale, the insider now directly owns 250,678 shares of the company’s stock, valued at approximately $383,537.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 259,352 shares of company stock valued at $399,373 over the last ninety days. 7.10% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in EKSO. Independence Advisors LLC purchased a new stake in Ekso Bionics Holdings during the 2nd quarter worth about $1,840,000. Carl Domino Inc lifted its holdings in Ekso Bionics Holdings by 74.7% during the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after buying an additional 35,088 shares during the last quarter. National Planning Corp lifted its holdings in Ekso Bionics Holdings by 116.2% during the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock worth $537,000 after buying an additional 126,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Ekso Bionics Holdings by 32.9% during the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after buying an additional 176,197 shares during the last quarter. Finally, Intellectus Partners LLC lifted its holdings in Ekso Bionics Holdings by 5.3% during the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after buying an additional 5,294 shares during the last quarter. 6.04% of the stock is owned by institutional investors.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.